Evidence map›Paper›PMID 31827798›Full record

ArticleBiomarker research2019

Clinical significance of stromal ER and PR expression in periampullary adenocarcinoma.

Gustav Andersson, Sebastian Lundgren, Margareta Heby, Björn Nodin, Jacob Elebro, Karin Jirström

Open access · goldAbstract read
In one paragraph

Article in Biomarker research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Gustav AnderssonDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.ORCID 0000-0003-3956-4252
Sebastian LundgrenDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Margareta HebyDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Björn NodinDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Jacob ElebroDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Karin JirströmDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Lund University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTamoxifen treatment has previously been reported to confer life-prolonging effects in patients with advanced pancreatic cancer, and most evidently so in women. None of these trials did however include biomarkers, and the relevance of female hormone signaling in pancreatic or other periampullary adenocarcinoma remains largely unexplored. The aim of this study was to examine the extent and potential clinical significance of estrogen receptor-α (ER) and progesterone receptor (PR) expression in pancreatic and other periampullary cancers.

methodsER and PR expression was examined using immunohistochemistry on tissue microarrays with primary tumors from a retrospective consecutive cohort of 175 patients with resected periampullary adenocarcinoma, with long-term clinical follow-up. Non-parametric and Chi square tests were applied to examine the associations of stromal ER and PR expression with patient and tumor characteristics. Kaplan-Meier analysis and log rank test were applied to illustrate survival differences in relation to ER and PR expression. Cox regression proportional hazards models were applied to examine the associations between investigative factors and risk of death and recurrence, and to test for interactions between

resultsExpression of both ER and PR was more frequent in the tumor-associated stroma than in the epithelium. A significant prognostic interaction, independent of tumor morphology, was found between stromal PR expression and

conclusionsThese results demonstrate that stromal PR rather than ER expression, together with

Indexed as

Estrogen receptorKRASPancreatic cancerPeriampullary adenocarcinomaProgesterone receptorPrognosis

Identifiers

PMID31827798
PMCPMC6862740
OpenAlexW2990720934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.